Company / Cost of Revenue
RHYTHM PHARMACEUTICALS, INC. Cost of Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$19.5M
FY2025
5-year range
$599.0K / $19.5M
FY2021-FY2025
Trend
+45.8%
vs FY2024
Sector context
#65 of 85
Health Care
What the data says
RHYTHM PHARMACEUTICALS, INC.'s cost of revenue of $19M is lower than 76% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 4 consecutive years, from $599,000 in FY2021 to $19M in FY2025.
Based on SEC 10-K filings.
$19M in FY2025 with a 3-year CAGR of +109.1%.
Increased from $9M to $19M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +109.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 24% in Health CareTop 24% of 85This company $19.5M Sector average $2.0B
▼
-99.0% below sector average
Key checks
Key Insights
- RHYTHM PHARMACEUTICALS, INC.'s cost of revenue has grown for 4 consecutive years.
- 3-year CAGR of +109.1%, indicating consistent growth.
- In FY2025, cost of revenue increased 45.8% year-over-year.
- Ranks #65 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -2.52 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.5M | +45.8% |
| FY2024 | $13.4M | +43.7% |
| FY2023 | $9.3M | +336.1% |
| FY2022 | $2.1M | +256.1% |
| FY2021 | $599.0K | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026